JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition
Anna Sophia McKenney, … , Craig B. Thompson, Ross L. Levine
Anna Sophia McKenney, … , Craig B. Thompson, Ross L. Levine
Published September 17, 2018
Citation Information: J Clin Invest. 2018;128(10):4743-4743. https://doi.org/10.1172/JCI124920.
View: Text | PDF | Amended Article
Corrigendum

JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

Abstract

Authors

Anna Sophia McKenney, Allison N. Lau, Amritha Varshini Hanasoge Somasundara, Barbara Spitzer, Andrew M. Intlekofer, Jihae Ahn, Kaitlyn Shank, Franck T. Rapaport, Minal A. Patel, Efthymia Papalexi, Alan H. Shih, April Chiu, Elizaveta Freinkman, Esra A. Akbay, Mya Steadman, Raj Nagaraja, Katharine Yen, Julie Teruya-Feldstein, Kwok-Kin Wong, Raajit Rampal, Matthew G. Vander Heiden, Craig B. Thompson, Ross L. Levine

×

Full Text PDF | Download (106.81 KB)